GlassScriptPhysician profile
Marian Couto
NPI 1013166586
$3,137.10
in general payments reported to CMS, 2019-2025
17 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $337 · 2021: $94.94 · 2022: $408 · 2023: $620 · 2024: $498 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.30 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $687.85 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $290.73 | 2019-2023 | Ffr Link, Opticross |
| Astrazeneca Pharmaceuticals LP | $241.40 | 2019-2024 | Farxiga, Lokelma, Brilinta |
| Bayer Puerto Rico INC. | $229.28 | 2023-2025 | Kerendia |
| Pbg Puerto Rico LLC | $225.23 | 2019-2025 | |
| Abbott Laboratories | $104.96 | 2019-2023 | Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $102.29 | 2023-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $100.37 | 2019 | |
| Amgen INC. | $77.04 | 2024-2025 | Repatha, Repatha |
| Medtronic, INC. | $73.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.99 | 2022-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $57.78 | 2022-2023 | Verquvo |
| Scpharmaceuticals INC. | $53.16 | 2025 | |
| Biotronik INC. | $24.49 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.01 | 2024 | |
| Pfizer Pharmaceuticals LLC | $16.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Couto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.